What To Know
- Sean Brown has also held leadership roles in global facilities and operations with Bristol-Myers Squibb’s radionuclide division and led Technical Services at AstraZeneca, where his responsibilities included tech transfer, scale up, and regulatory submissions for clinical and commercial manufacturing of small molecule formulations for parenteral and sterile products.
- “Sean’s depth and breadth of experience in leading manufacturing operations for a variety of products is truly impressive and we are fortunate to have attracted such a talented leader,”.
Sean Brown brings over 30 years of experience in clinical and commercial operations in the biopharmaceutical industry and Cell and Gene Therapies (CGTs).
Prior to joining iVexSol he was a Partner with BW Design Group, where he directed specialized teams for engineering, construction, and validation for a variety of biologics and CGT projects.
Sean Brown has also held leadership roles in global facilities and operations with Bristol-Myers Squibb’s radionuclide division and led Technical Services at AstraZeneca, where his responsibilities included tech transfer, scale up, and regulatory submissions for clinical and commercial manufacturing of small molecule formulations for parenteral and sterile products. He graduated from University of Warwick’s, Business Process Management program and holds a B.Sc. in Engineering from the University of Massachusetts.
“Sean’s depth and breadth of experience in leading manufacturing operations for a variety of products is truly impressive and we are fortunate to have attracted such a talented leader,” said iVexSol co-founder & CEO Rod Rietze. “We welcome him to our executive leadership team and look forward to working closely with him as we bring our manufacturing operations online and begin meeting our clients’ vector needs.”
“I am very honored to join an accomplished leadership team responsible for delivering transformational technology and operational innovations to dramatically improve lentiviral vector supply accelerating patient care for unmet medical needs,” said Mr. Brown. “iVexSol will deliver important scientific advancements to our customers that will establish secure and reliable supply to the market.”